Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883636 · ClinicalTrials.gov registry record
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
A clinical trial, sponsored by Northwell Health.
- Terminated
- Registry status
- 4
- Enrollment target
NCT00883636: Clinical Trial study, sponsored by Northwell Health.
NCT00883636 is a clinical trial that was terminated before completion, run by Northwell Health. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00883636 was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS * Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities * Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality
Primary Outcome
Presence or Absence of any of the podocin gene mutations 1. podocin gene (NPHS2) 2. CD2-associated protein (CD2AP) 3. actinin-4 (ACTN4) 4. Nephrotic syndrome steroid-resistant gene (SRN1) 5. Wilms Tumor 1(WT1) 6. Transient receptor potential cation channel, subfamily C, member 6 (TRPC6) 7. Phospholipase C-E1 (PLCE-1)
Interventions
- OTHER Cardiovascular Assessment
- OTHER Renal Assessment
- OTHER Genetic Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-10 |
Why NCT00883636 stopped before completion
NCT00883636 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Cardiovascular Assessment is the first listed.
NCT00883636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00883636 about?
NCT00883636 is a clinical study titled "Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis". The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incide...
What is the current status of trial NCT00883636?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2008-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00883636?
The interventions under investigation include: Cardiovascular Assessment (OTHER), Renal Assessment (OTHER), Genetic Evaluation (OTHER).
Who is sponsoring clinical trial NCT00883636?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia